Recent Transactions

30-Dec-22
$153 million
United States flag
Target: 

Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products

Australia flag
Acquiror: 
Mayne Pharma

Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma

13-Oct-22
$47 million
Australia flag
Target: 

Electro Optic Systems

Australia flag
Acquiror: 
Washington H. Soul Pattinson

Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson

17-Dec-21
N.A.
United States flag
Target: 

MRO Holdings, Inc. (Panama)

flag not available
Acquiror: 
N.A.

Advised MRO Holdings, a leading airframe maintenance, repair and overhaul (“MRO”) services provider in the Americas, on its term loan financing

11-Mar-21
$2.1 billion
Australia flag
Target: 

Education Australia’s 40% Stake in IDP Education

Australia flag
Acquiror: 
Education Australia’s 38 University Shareholders

Advising ASX-listed IDP Education on the restructure of Education Australia’s 40% ownership stake in the business

29-Sep-20
$200 million
United States flag
Target: 

Travel & Transport

Australia flag
Acquiror: 
Corporate Travel Management

Advising Corporate Travel Management on its acquisition of US-based travel management company Travel & Transport and the associated A$375mm equity raise 

02-May-18
$3.7 billion
Canada flag
Target: 

Concordia International Corp.

flag not available

Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt

13-Oct-16
$NA
U.S.A., Canada flags
Target: 

Concordia International Corp

flag not available

Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process

04-Oct-16
$223 million
U.S.A., U.K. flags
Target: 

US rights to Toprol-XL (AstraZeneca)

Canada flag
Acquiror: 
Aralez Pharmaceuticals Inc.

Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.

19-Jan-16
$NA
Brazil flag
Target: 

Recepta Biopharma

Brazil flag
Acquiror: 
Inova Empresa Fundo de Investimento em Participações

Advised Recepta Biopharma on a capital raise

21-Apr-15
$963 million
flag not available
Target: 

Refinancing of syndicated bank debt facilities

Australia flag
Acquiror: 
Primary Health Care

Advised Primary Health Care on the refinancing of its A$1.25 billion syndicated bank debt facilities

30-Mar-15
$950 million
United Kingdom flag
Target: 

Quindell plc’s Professional Services Division

Australia flag
Acquiror: 
Slater and Gordon

Advised Slater and Gordon Limited, an ASX-listed international consumer law firm, on the acquisition of Quindell plc’s Professional Services Division, the UK’s leading personal injury law firm operating across the claims value chain, and associated A$890 million equity and A$375 million debt raisings

23-Oct-14
$NA
Australia flag
Target: 

Boart Longyear Ltd.

flag not available

Advised the Board of Directors of Boart Longyear, the world’s leading supplier of drilling services and equipment for mining and drilling companies, on its strategic review process and subsequent comprehensive recapitalization transactions with certain affiliates of Centerbridge Partners, L.P.

13-May-11
$NA
Australia flag
Target: 

Bionomics Ltd

Advised Bionomics Ltd, in relation to the tender process run by Bionomics’ largest shareholder, Start-up Australia Ventures (“Start-up”), for its 28% stake in the company, follow on sell-down of Start-up’s stake to 8% and associated capital raising by Bionomics

16-Jul-01
$982 million
United States flag
Target: 

Sterling Chemicals

Advised Sterling Chemicals in connection with its Chapter 11 proceedings

show all